Clinical Trials Browser

Phase 1/2 × Lung Neoplasms × patritumab × Clear all

NCT01211483 2021-06-16

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1/2 Completed

222 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms